[D-Arg²⁵]-NPY functions as a broad-spectrum NPY receptor agonist, binding to Y₁, Y₂, Y₄, and Y₅ receptors with high affinity and coupling to Gi/o proteins to inhibit adenylate cyclase, leading to reduced intracellular cAMP levels. This signaling cascade activates inwardly rectifying potassium channels and inhibits voltage-gated calcium channels, resulting in neuronal hyperpolarization, decreased neurotransmitter release, and modulation of various physiological processes. The D-arginine substitution at position 25 enhances resistance to proteolytic degradation by endopeptidases, prolonging the peptide's half-life and duration of action without significantly altering receptor binding properties, thereby providing sustained activation of NPY receptor pathways.

This metabolically stabilized NPY analog is indicated exclusively for research applications requiring prolonged NPY receptor activation. It is employed in NPY receptor binding and autoradiography studies across multiple subtypes, functional assays measuring sustained cAMP inhibition and calcium signaling, feeding behavior and energy homeostasis research with extended duration of effect, anxiety and stress response models requiring chronic NPY exposure, cardiovascular function studies investigating prolonged vasoconstriction and blood pressure modulation, and validation of NPY receptor expression and signaling in various tissues. The product serves as a reference agonist for screening NPY receptor antagonists and studying the role of sustained NPY signaling in obesity, metabolic disorders, anxiety, and cardiovascular diseases. It is not intended for diagnostic, therapeutic, or clinical use.

As a research reagent, [D-Arg²⁵]-Neuropeptide Y, human, rat has no established clinical efficacy or safety profile for therapeutic applications. The peptide has not undergone clinical trials, regulatory approval, or safety evaluation for any medical indication. While it contributes to fundamental understanding of NPY receptor biology and may inform the development of future therapeutic agents targeting NPY receptors for obesity, metabolic disorders, anxiety, or cardiovascular conditions, its utility remains confined to preclinical research. Any clinical translation would require development of entirely distinct therapeutic agents with comprehensive preclinical and clinical testing.